Veracyte Inc.
40.98
-1.80 (-4.21%)
At close: Jan 14, 2025, 3:59 PM
41.06
0.20%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 40.21
Market Cap 3.18B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.13
PE Ratio (ttm) -315.23
Forward PE n/a
Analyst Buy
Ask 45
Volume 501,770
Avg. Volume (20D) 760,280
Open 43.09
Previous Close 42.78
Day's Range 40.25 - 43.52
52-Week Range 18.61 - 46.00
Beta undefined

About VCYT

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test ...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 30, 2013
Employees 815
Stock Exchange NASDAQ
Ticker Symbol VCYT

Analyst Forecast

According to 7 analyst ratings, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 2.49% from the latest price.

Buy 71.43%
Hold 14.29%
Sell 14.29%
Stock Forecasts

Next Earnings Release

Veracyte Inc. is scheduled to release its earnings on Feb 20, 2025, during market hours.
Analysts project revenue of $115.07M, reflecting a 17.18% YoY growth and earnings per share of 0.05, making a 0.00% YoY.
2 months ago · Source
+2.05%
Veracyte shares are trading higher after the compa... Unlock content with Pro Subscription
5 months ago · Source
+23.97%
Veracyte shares are trading higher after the company reported better-than-expected Q2 financial results. Also, Needham maintained a Buy rating on the stock and raised its price target from $27-$31.